What If Theranos Was A Hedge Fund?Advisor Perspectives
The amazing story of Theranos, a company started in 2003 by a 19-year-old Stanford dropout, is told in page-turning detail in a recent book by Wall Street Journal reporter John Carreyrou. Despite an incredibly distinguished board, leading venture capital investors, raves from a respected Stanford dean and contracts with consumer chains Walgreen and Safeway, the company’s claims were finally revealed in 2015 to have been fraudulent.
But what if Theranos had been a hedge fund instead of a healthcare company? The comparison shows why investment “science” is not science.
The story of Theranos
Elizabeth Holmes always had her sights set high. Carreyrou records that at age nine or 10 when she was asked, “What do you want to do when you grow up?” she said without hesitation, “I want to be a billionaire.”
As a Stanford student in 2003, she spent a summer in Singapore testing the blood of patients suspected of carrying the severe acute respiratory syndrome (SARS) virus. It convinced her there must be a better way to test blood.
In late 2003, at the age of 19, with the help of Stanford’s School of Engineering Associate Dean Channing Robertson, in whose laboratory she had worked, she incorporated the company that would become Theranos and dropped out of college. Theranos’s goal was to perform a wide range of blood tests with only the blood from a finger-prick, using a miniaturized analytic device.
With Robertson’s and Stanford’s network, and Holmes’ charisma and impressive delivery of her idea, she quickly acquired funding and staffed up. She gave successful presentations of the technology to major companies like the Swiss pharmaceutical giant Novartis.
But as early as 2006 some of her staff noticed that the technology presented to Novartis was fake. Depicted as a video of a blood sample being processed in real-time by the miniature analyser, the video actually was a recording of a successful test that had been performed earlier. The analyser usually didn’t work.
When Theranos’s CFO learned of this he told Holmes, “We’ve been fooling investors. We can’t keep doing that.” As soon as he told her that, he was summarily fired.
This scenario was played out again and again. Tests that were supposedly done by the microanalyzer using blood from a finger-prick were actually done by a large conventional Siemens analyzer using a venous draw. Anyone who expressed scepticism or pointed out that the technology wasn’t working was forced out of the company. Turnover was extremely high. Employees had been required to sign very restrictive non-disclosure agreements upon hiring, and were made to turn over all documents and devices upon departure as well as to sign additional restrictive agreements.
Management by Holmes and particularly her second-in-command (and secretly, boyfriend) Sunny Balwani was aggressively autocratic. Theranos departments, even those that should have been working together, were kept apart by reporting separately to Holmes so that they would not share information. Departed employees who might go public with information detrimental to the company were threatened with lawsuits by the law firm of David Boies, probably the most prominent attorney in America, on the pretext of protecting trade secrets; just how frightening became crystal clear to Carreyrou and his sources in 2015 as he pieced together his eventual article unmasking Theranos’s fraud.
This continued, astonishingly enough, for more than a decade. Meanwhile, glowing articles were written about Holmes and Theranos in numerous magazines and newspapers, including Fortune, Forbes, USA Today, Inc., Fast Company, Glamour and The Wall Street Journal itself. Segments were heard on radio and seen on television stations. Her board of directors included former secretaries of state Henry Kissinger and George Schultz, General James Mattis, and other prominent individuals.
When Carreyrou’s article was published in The Wall Street Journal on October 16, 2015, it began the unravelling of the company. Eventually, its largest investor, Rupert Murdoch, who had invested $125 million, sold his shares back to Theranos for one dollar to take the tax loss. Holmes, Balwani, and Theranos were charged with “massive fraud” by the SEC. If it hadn’t been for Carreyrou, the fraud – which caused actual harm to patients – might have continued for years.
What if Theranos had been a hedge fund?
Now let’s go beyond what Carreyrou wrote and change the scenario. Elizabeth Holmes comes up with a brilliant-sounding idea for an investment strategy using complex derivatives. With her charisma, hypnotic presentation skills, networking abilities and radiant intelligence, she quickly raises seed capital for a hedge fund.
She hires top investment talent and makes them sign strict non-disclosure agreements, keeping them separated from each other to prevent leaks. Understandably, she goes to great lengths to ensure that anyone who leaves the company does not reveal information about it, including hiring the top law firm in the nation, known for its tactics of intimidation.
After a little while it is discovered internally that her original brilliant-sounding investment strategy doesn’t work very well. But it is now only one of many strategies being tested and deployed by her by-now large staff. Results for most of these strategies are ho-hum, but they are written off with unverifiable explanations, such as that they are strategies that protect against down markets while slightly underperforming in up markets. Furthermore, of the many strategies being tested and used, there are one or two that have succeeded, so far, moderately well, though they are run-of-the-mill long-equity investment strategies departing only in small ways from closet-index funds.
Arcane quantitative measures and performance goals are adapted and devised to show that the funds are meeting their objectives. The results are presented in complicated PowerPoints to potential and existing investors, and to consulting firms, who nod their heads affirmatively. The PowerPoints continue to highlight the original strategy using complex options, conveying the impression that this is the strategy being used.
Mostly, though, the investment results do not come close to matching the initial exuberant hype. Holmes says it takes time for her investment strategy to work. The institutions and wealthy investors in her funds and their consultants are still impressed by her and stay with her, saying they “aren’t concerned about the short-term performance of these funds.”
Holmes co-authors articles with prominent academics, who are on her payroll, using complicated-looking mathematics, reaching bold conclusions that support the strategies her funds use (but to a discerning eye, don’t agree with the mathematics). These articles are published in peer-reviewed financial journals, helped by the fact that her co-authors and reviewers understand how that system works. She speaks regularly at conferences, and is the frequent subject of admiring articles in magazines and newspapers.
Read the full article here by Michael Edesess, Advisor Perspectives